If you have been reading about Lipodystrophy and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
This is based on the absence of Neanderthal mtDNA, as well as the relatively low level of Neanderthal admixture in the modern human X chromosome. According to Svante Pääbo, it is not clear that modern humans were socially dominant over Neanderthals, which may explain why the interbreeding occurred primarily between Neanderthal males and modern human females. A 2026 study confirmed the evidence of sex bias, reporting that sexual selection (i.e., a preference for male Neanderthals and modern human females) was the primary driver of the asymmetric mating patterns, rather than sex biases in demography or migration. Neanderthals in the Siberian Altai Mountains interbred with the local Denisovan population, and it may have been a common occurrence here. About 17% of the genome of one Altai Denisovan specimen derived from Neanderthals. Even before genetic evidence had confirmed this admixture, hybridisation between Neanderthals and early modern humans had been proposed early on, such as by English anthropologist Thomas Huxley in 1890, Danish ethnographer Hans Peder Steensby in 1907, and Coon in 1962. In the early 2000s, supposed hybrid specimens were discovered: Lagar Velho 1 and Muierii 1. These proposals were based on shared anatomy, but modern geneticists have cautioned that some shared anatomy might have been acquired by adaptation to a similar environment, rather than admixture alone.
== Ownership and finance == Marks and Hazan initially supported GYG with their own money. In 2009, they sold a minority stake to Peter Ritchie, Guy Russo and Steve Jermyn, who had previously been involved with McDonald's Australia. Russo was subsequently appointed chairman of the board. The board also includes co-founder Robert Hazan, Tom Cowan of TDM Growth Partners, Rokt CEO Bruce Buchanan, and three former McDonalds executives. Investment firm TDM Growth Partners bought a stake in the company for $44 million in August 2018. In December 2020, the publicly listed Magellan Financial Group bought 10% of the company for $86.8 million. In May 2022, Magellan sold its 11.6% stake in the company to an entity owned by investment bank Barrenjoey Capital Partners for $140 million. Marks stated in 2019 that his goal was to list GYG on the Australian Securities Exchange. In 2020, he stated that he was also ambitious to expand the company's presence in the United States, citing Australia's "antiquated" labour laws, high rents, and expensive fresh produce. Marks resigned as CEO due to a health scare in May 2023, but he changed his mind and remained. Hilton Brett was appointed co-CEO in October 2023. GYG was listed on the Australian Securities Exchange on 20 June 2024.
== History == NCYC were founded in 1948 when a group of British brewers, who later formed the Brewing Industry Research Foundation, decided to store their yeast cultures in a single, safe deposit to ensure their longevity. In 1981 NCYC evolved into a broader collection when it moved to Institute of Food Research. in Norwich, in which it collected food spoilage yeast which was able to evade the conventional food preservatives. In 1999, the collection became a part of The United Kingdom National Culture Collection (UKNCC)., which was established to co-ordinate the activities of Britain’s national collections of microbial organisms. In 2019, the collection moved to the new facility in Quadram Institute Biosciences in the Norwich Research Park where it is currently based. NCYC trades under QIB Extra Ltd, a wholly owned commercial subsidiary of the Quadram Institute Bioscience, based at the Quadram Institute that specialises in bespoke research services for the food, health and allied industries.
"The discovery of radium". Lateral Science. UK. 8 July 2012. Archived from the original on 9 March 2016. Retrieved 13 May 2017. Radium water bath in Oklahoma. markwshead.com (photographic images). "Radium, radioactive". NLM Hazardous Substances Databank. U.S. National Institutes of Health. Archived from the original on 1 July 2018. "Annotated bibliography for radium". Alsos Digital Library for Nuclear Issues. Lexington, VA: Washington and Lee University. Archived from the original on 25 June 2019. "Radium". The Periodic Table of Videos. University of Nottingham.
Sources: en.wikipedia.org
18 February 1919: In spite of the ceasefire, there is fighting near Rynarzewo. The Poles capture the armoured train. 9 February 1919: A volunteer company of Great Polish soldiers moves to Lesser Poland to fight against the Ukrainians. 20 March 1919: The Ostmarkenzulage, a special allowance for German officials working in the eastern provinces to stimulate the German colonization of the Prussian Partition, is canceled. 23 March 1919: The Poles win a landslide in elections to the city council of Poznań. 24 March 1919: The Commission of the NRL asks the Polish government in Warsaw to create separate administration of the former Prussian Partition, as it is far more developed than the rest of the country. Ignacy Paderewski forces the government to leave all power in hands of the NRL until the final recognition of Polish-German border, with later autonomy there (only Upper Silesia would obtain it). The NRL mobilises men born in 1891, 1892, 1893, 1894 and 1901. 5 April 1919: The Sejm Ustawodawczy announces byelections in the former Province of Posen for next 42 MPs. 9 April 1919: The Commission of the NRL decrees an eight-hour workday in industry and trade. 10 April 1919: The Commission of the NRL decrees the removal of signs in German language from offices and train stations the changing of all streets names into Polish. The punishment for breaking the law is two years of prison and a fine of Mp. 10,000. 16 April 1919: The NRL decides that 3 May is the national holiday. 7 May 1919: The Wszechnica Piastowska is opened. 15 May 1919: Polish becomes the only official language.
== Drugs withdrawn == The following therapeutic drugs were withdrawn from the market primarily because of hepatotoxicity: Troglitazone, bromfenac, trovafloxacin, ebrotidine, nimesulide, nefazodone, ximelagatran and pemoline.
=== Travel distances === Teams participating in the 2026 World Cup had to travel an average of 5,146 total miles (8,281.7 km) between venues during the tournament. For the 2014 tournament in Brazil, the average distance was 7,054 miles (11,352.2 km), while teams playing in the 2018 tournament in Russia traveled an average of 5,441 miles (8,756.4 km).
== Data == SIRIUS is using data from liquid-chromatography tandem mass spectrometry (LC-MS/MS). It requires high-resolution, high mass accuracy MS1 and MS2 data as input. LC is not mandatory for SIRIUS, however is often required to separate individual compounds in complex samples.
GLOBSEC – Global think tank committed to enhancing security, prosperity and sustainability in Europe and throughout the world. Central European Labour Studies Institute or CELSI (Stredoeurópsky inštitút pre výskum práce in Slovak) – Central-european think tank which specializes in broadly defined labor issues, labour markets, and labor policy. Forum Minority Research Institute (Fórum Kisebbségkutató Intézet or Fórum Intézet in Hungarian and Fórum inštitút pre výskum menšín or Fórum inštitút in Slovak) – Think tank focusing on ethnic minorities living in Slovakia, especially Hungarians. International think tanks with presence in Slovakia:
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。